May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
New Therapeutic Approach in Macular Degeneration: IOL VIP System
Author Affiliations & Notes
  • E. Balestrazzi
    Ophthalmology, University of L'Aquila, L'Aquila, Italy
  • P. Iorio
    Ophthalmology, University of L'Aquila, L'Aquila, Italy
  • L. Mosca
    Ophthalmology, Catholic University of the Sacred Heart, Roma, Italy
  • R. Fasciani
    Ophthalmology, University of L'Aquila, L'Aquila, Italy
  • Footnotes
    Commercial Relationships  E. Balestrazzi, None; P. Iorio, None; L. Mosca, None; R. Fasciani, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4586. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Balestrazzi, P. Iorio, L. Mosca, R. Fasciani; New Therapeutic Approach in Macular Degeneration: IOL VIP System . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4586.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate the efficacy and safety of IOL VIP (intraocular lens for visually impaired people) implantation in low vision patients affected by macular degeneration. Methods: The system consists in both a rehabilitation and a surgical procedure studied to improve vision capabilities. The surgical technique consists in a phacoemulsification of the cataract followed by implantation of two IOLs: one in the bag and one in the anterior chamber. These two IOLs realize a Galileian telescopic system (with 1.3 X magnification). The practice with a special software allows patients to use IOL VIP implant. 16 patients, affected by different macular pathologies (Age Related Macular Degeneration, Pathologic Myopia, Stargardt Maculopathy) were submitted to IOL VIP implantation (9 in both eyes; 7 in one eye). Mean preoperative far BCVA was 20.67 letters of ETDRS chart (+/–9.08SD) and near BCVA was 3.50J+/–1.53SD. Results: All treated patients reached an improvement in both visual acuity and reading ability, without reduction of peripheral vision field. After 3 months, the mean postoperative far BCVA results of 33.24 ETDRS letters (+/–6.98SD) with a near BCVA of 1.83J +/–1.53SD). Furthermore, patients referred sensible raise in quality of life. Conclusions: IOL VIP system seems to be a safe and effective combined therapeutic technique for central low vision patients.

Keywords: low vision • clinical (human) or epidemiologic studies: systems/equipment/techniques 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.